Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples.

Toomey S, Carr A, Mezynski MJ, Elamin Y, Rafee S, Cremona M, Morgan C, Madden S, Abdul-Jalil KI, Gately K, Farrelly A, Kay EW, Kennedy S, O'Byrne K, Grogan L, Breathnach O, Morris PG, Eustace AJ, Fay J, Cummins R, O'Grady A, Kalachand R, O'Donovan N, Kelleher F, O'Reilly A, Doherty M, Crown J, Hennessy BT.

J Transl Med. 2020 Feb 22;18(1):99. doi: 10.1186/s12967-020-02273-4.

PMID:
32087721
2.

Mucinous adenocarcinoma is a pharmacogenomically distinct subtype of colorectal cancer.

Reynolds IS, O'Connell E, Fichtner M, McNamara DA, Kay EW, Prehn JHM, Furney SJ, Burke JP.

Pharmacogenomics J. 2019 Dec 10. doi: 10.1038/s41397-019-0137-6. [Epub ahead of print]

PMID:
31819162
3.

Correction to: LC3B globular structures correlate with survival in esophageal adenocarcinoma.

El-Mashed S, O'Donovan TR, Kay EW, Abdallah AR, Cathcart MC, O'Sullivan J, O'Grady A, Reynolds J, O'Reilly S, O'Sullivan GC, McKenna SL.

BMC Cancer. 2019 Dec 3;19(1):1177. doi: 10.1186/s12885-019-6410-x.

4.

Mucinous adenocarcinoma of the colon and rectum: A genomic analysis.

Reynolds IS, O'Connell E, Fichtner M, McNamara DA, Kay EW, Prehn JHM, Furney SJ, Burke JP.

J Surg Oncol. 2019 Dec;120(8):1427-1435. doi: 10.1002/jso.25764. Epub 2019 Nov 14.

PMID:
31729037
5.

Karyomegalic Interstitial Nephritis: Cancer Risk Following Transplantation.

Murray SL, Connaughton DM, Fennelly NK, Kay EW, Dorman A, Doyle B, Conlon PJ.

Nephron. 2020;144(1):49-54. doi: 10.1159/000503034. Epub 2019 Oct 25.

PMID:
31655823
6.

Mucin Pools Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Marker of Response or Epiphenomenon?

Reynolds IS, O'Connell E, Fichtner M, Kay EW, McNamara DA, Prehn JHM, Burke JP.

Am J Surg Pathol. 2020 Feb;44(2):280-287. doi: 10.1097/PAS.0000000000001373.

PMID:
31567193
7.

Correction: BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer.

Shields S, Conroy E, O'Grady T, McGoldrick A, Connor K, Ward MP, Useckaite Z, Dempsey E, Reilly R, Fan Y, Chubb A, Matallanas DG, Kay EW, O'Connor D, McCann A, Gallagher WM, Coppinger JA.

Oncotarget. 2019 May 3;10(33):3144. doi: 10.18632/oncotarget.26920. eCollection 2019 May 3.

8.

A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic.

Salvucci M, Rahman A, Resler AJ, Udupi GM, McNamara DA, Kay EW, Laurent-Puig P, Longley DB, Johnston PG, Lawler M, Wilson R, Salto-Tellez M, Van Schaeybroeck S, Rafferty M, Gallagher WM, Rehm M, Prehn JHM.

JCO Clin Cancer Inform. 2019 Apr;3:1-17. doi: 10.1200/CCI.18.00056.

9.

Meta-analysis of the molecular associations of mucinous colorectal cancer.

Reynolds IS, Furney SJ, Kay EW, McNamara DA, Prehn JHM, Burke JP.

Br J Surg. 2019 May;106(6):682-691. doi: 10.1002/bjs.11142. Epub 2019 Apr 4.

PMID:
30945755
10.

Mucin glycoproteins block apoptosis; promote invasion, proliferation, and migration; and cause chemoresistance through diverse pathways in epithelial cancers.

Reynolds IS, Fichtner M, McNamara DA, Kay EW, Prehn JHM, Burke JP.

Cancer Metastasis Rev. 2019 Jun;38(1-2):237-257. doi: 10.1007/s10555-019-09781-w.

PMID:
30680581
11.

Analytical validation of a prognostic prostate cancer gene expression assay using formalin fixed paraffin embedded tissue.

Medlow PW, Steele CJ, McCavigan AM, Reardon W, Brown CM, Lambe SM, Ishiy FAA, Walker SM, Logan GE, Raji OY, Berge V, Katz B, Kay EW, Sheehan K, Watson RW, Harkin DP, Kennedy RD, Knight LA.

BMC Med Genomics. 2018 Dec 27;11(1):125. doi: 10.1186/s12920-018-0442-y.

12.

Caspase-11 regulates the tumour suppressor function of STAT1 in a murine model of colitis-associated carcinogenesis.

Flood B, Manils J, Nulty C, Flis E, Kenealy S, Barber G, Fay J, Mills KHG, Kay EW, Creagh EM.

Oncogene. 2019 Apr;38(14):2658-2674. doi: 10.1038/s41388-018-0613-5. Epub 2018 Dec 11.

13.

Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.

Leech AO, Vellanki SH, Rutherford EJ, Keogh A, Jahns H, Hudson L, O'Donovan N, Sabri S, Abdulkarim B, Sheehan KM, Kay EW, Young LS, Hill ADK, Smith YE, Hopkins AM.

Breast Cancer Res. 2018 Nov 20;20(1):140. doi: 10.1186/s13058-018-1064-1.

14.

Measurement of the IgM and IgG Autoantibody Immune Responses in Human Serum has High Predictive Value for the Presence of Colorectal Cancer.

Fitzgerald S, O'Reilly JA, Wilson E, Joyce A, Farrell R, Kenny D, Kay EW, Fitzgerald J, Byrne B, Kijanka GS, O'Kennedy R.

Clin Colorectal Cancer. 2019 Mar;18(1):e53-e60. doi: 10.1016/j.clcc.2018.09.009. Epub 2018 Sep 27.

PMID:
30366678
15.

The significance of mucin pools following neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

Reynolds IS, McNamara DA, Kay EW, O'Neill B, Deasy J, Burke JP.

J Surg Oncol. 2018 Dec;118(7):1129-1134. doi: 10.1002/jso.25247. Epub 2018 Sep 27.

PMID:
30261095
16.

Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.

van Dijk E, Biesma HD, Cordes M, Smeets D, Neerincx M, Das S, Eijk PP, Murphy V, Barat A, Bacon O, Prehn JHM, Betge J, Gaiser T, Fender B, Meijer GA, McNamara DA, Klinger R, Koopman M, Ebert MPA, Kay EW, Hennessey BT, Verheul HMW, Gallagher WM, O'Connor DP, Punt CJA, Loupakis F, Lambrechts D, Byrne AT, van Grieken NCT, Ylstra B.

J Clin Oncol. 2018 Jul 10;36(20):2052-2060. doi: 10.1200/JCO.2017.77.1782. Epub 2018 May 24.

PMID:
29792754
17.

BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer.

Shields S, Conroy E, O'Grady T, McGoldrick A, Connor K, Ward MP, Useckaite Z, Dempsey E, Reilly R, Fan Y, Chubb A, Matallanas DG, Kay EW, O'Connor D, McCann A, Gallagher WM, Coppinger JA.

Oncotarget. 2018 Feb 28;9(21):15673-15690. doi: 10.18632/oncotarget.24590. eCollection 2018 Mar 20. Erratum in: Oncotarget. 2019 May 3;10(33):3144.

18.

Stromal TRIM28-associated signaling pathway modulation within the colorectal cancer microenvironment.

Fitzgerald S, Espina V, Liotta L, Sheehan KM, O'Grady A, Cummins R, O'Kennedy R, Kay EW, Kijanka GS.

J Transl Med. 2018 Apr 10;16(1):89. doi: 10.1186/s12967-018-1465-z.

19.

The BAX/BAK-like protein BOK is a prognostic marker in colorectal cancer.

Carberry S, D'Orsi B, Monsefi N, Salvucci M, Bacon O, Fay J, Rehm M, McNamara D, Kay EW, Prehn JHM.

Cell Death Dis. 2018 Jan 26;9(2):125. doi: 10.1038/s41419-017-0140-2.

20.

The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.

Hannan EJ, O'Leary DP, MacNally SP, Kay EW, Farrell MA, Morris PG, Power CP, Hill ADK.

Medicine (Baltimore). 2017 Dec;96(48):e8404. doi: 10.1097/MD.0000000000008404.

21.

Bilateral Adrenalectomy for Metastatic Esophageal Adenocarcinoma: A Case Report.

McNevin CS, Gleeson JP, Herlihy DB, Aird JJ, Robb WB, Kay EW, Morris PG, Grogan L, Breathnach OS.

J Oncol Pract. 2018 Jan;14(1):47-48. doi: 10.1200/JOP.2017.023713. Epub 2017 Sep 8. No abstract available.

PMID:
28885880
22.

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

Toomey S, Eustace AJ, Fay J, Sheehan KM, Carr A, Milewska M, Madden SF, Teiserskiene A, Kay EW, O'Donovan N, Gallagher W, Grogan L, Breathnach O, Walshe J, Kelly C, Moulton B, Kennedy MJ, Gullo G, Hill AD, Power C, Duke D, Hambly N, Crown J, Hennessy BT.

Breast Cancer Res. 2017 Jul 27;19(1):87. doi: 10.1186/s13058-017-0883-9.

23.

Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery.

Breen KJ, O'Neill A, Murphy L, Fan Y, Boyce S, Fitzgerald N, Dorris E, Brady L, Finn SP, Hayes BD, Treacy A, Barrett C, Aziz MA, Kay EW, Fitzpatrick JM, Watson RWG.

Prostate. 2017 Sep;77(12):1288-1300. doi: 10.1002/pros.23389. Epub 2017 Jul 20.

PMID:
28726241
24.

Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.

Walker SM, Knight LA, McCavigan AM, Logan GE, Berge V, Sherif A, Pandha H, Warren AY, Davidson C, Uprichard A, Blayney JK, Price B, Jellema GL, Steele CJ, Svindland A, McDade SS, Eden CG, Foster C, Mills IG, Neal DE, Mason MD, Kay EW, Waugh DJ, Harkin DP, Watson RW, Clarke NW, Kennedy RD.

Eur Urol. 2017 Oct;72(4):509-518. doi: 10.1016/j.eururo.2017.03.027. Epub 2017 Apr 10.

25.

Tamoxifen Suppresses the Growth of Malignant Pleural Mesothelioma Cells.

Jennings CJ, Zainal N, Dahlan IM, Kay EW, Harvey BJ, Thomas W.

Anticancer Res. 2016 Nov;36(11):5905-5913.

PMID:
27793915
26.

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.

Toomey S, Madden SF, Furney SJ, Fan Y, McCormack M, Stapleton C, Cremona M, Cavalleri GL, Milewska M, Elster N, Carr A, Fay J, Kay EW, Kennedy S, Crown J, Gallagher WM, Hennessy BT, Eustace AJ.

Oncotarget. 2016 Nov 15;7(46):75518-75525. doi: 10.18632/oncotarget.12782.

27.

Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.

Betge J, Barat A, Murphy V, Hielscher T, Van Grieken NC, Belle S, Zhan T, Härtel N, Kripp M, Bacon O, Cordes M, Kay EW, Verheul HM, Neerincx M, Hennessy B, Hofheinz RD, Gaiser T, Ylstra B, Prehn JH, Lambrechts D, Byrne AT, Ebert MP, Schulte N.

Digestion. 2016;94(3):129-137. doi: 10.1159/000449412. Epub 2016 Oct 19.

PMID:
27756074
28.

Expression of the TPα and TPβ isoforms of the thromboxane prostanoid receptor (TP) in prostate cancer: clinical significance and diagnostic potential.

Mulvaney EP, Shilling C, Eivers SB, Perry AS, Bjartell A, Kay EW, Watson RW, Kinsella BT.

Oncotarget. 2016 Nov 8;7(45):73171-73187. doi: 10.18632/oncotarget.12256.

29.

BCL-2 system analysis identifies high-risk colorectal cancer patients.

Lindner AU, Salvucci M, Morgan C, Monsefi N, Resler AJ, Cremona M, Curry S, Toomey S, O'Byrne R, Bacon O, Stühler M, Flanagan L, Wilson R, Johnston PG, Salto-Tellez M, Camilleri-Broët S, McNamara DA, Kay EW, Hennessy BT, Laurent-Puig P, Van Schaeybroeck S, Prehn JHM.

Gut. 2017 Dec;66(12):2141-2148. doi: 10.1136/gutjnl-2016-312287. Epub 2016 Sep 23.

PMID:
27663504
30.

A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer.

Salvucci M, Würstle ML, Morgan C, Curry S, Cremona M, Lindner AU, Bacon O, Resler AJ, Murphy ÁC, O'Byrne R, Flanagan L, Dasgupta S, Rice N, Pilati C, Zink E, Schöller LM, Toomey S, Lawler M, Johnston PG, Wilson R, Camilleri-Broët S, Salto-Tellez M, McNamara DA, Kay EW, Laurent-Puig P, Van Schaeybroeck S, Hennessy BT, Longley DB, Rehm M, Prehn JH.

Clin Cancer Res. 2017 Mar 1;23(5):1200-1212. doi: 10.1158/1078-0432.CCR-16-1084. Epub 2016 Sep 20.

31.

Erratum to: Calnexin, an ER stress-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer.

Ryan D, Carberry S, Murphy ÁC, Lindner AU, Fay J, Hector S, McCawley N, Bacon O, Concannon CG, Kay EW, McNamara DA, Prehn JH.

J Transl Med. 2016 Jul 26;14(1):222. No abstract available.

32.

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Toomey S, Eustace AJ, Pritzker LB, Pritzker KP, Fay J, O'Grady A, Cummins R, Grogan L, Kennedy J, O'Connor D, Young L, Kay EW, O'Donovan N, Gallagher WM, Kalachand R, Crown J, Hennessy BT.

J Natl Cancer Inst. 2016 Jul 4;108(8). pii: djw111. doi: 10.1093/jnci/djw111. Print 2016 Aug. No abstract available.

33.

Calnexin, an ER stress-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer.

Ryan D, Carberry S, Murphy ÁC, Lindner AU, Fay J, Hector S, McCawley N, Bacon O, Concannon CG, Kay EW, McNamara DA, Prehn JH.

J Transl Med. 2016 Jul 1;14(1):196. doi: 10.1186/s12967-016-0948-z. Erratum in: J Transl Med. 2016;14(1):222.

34.

The influence of anti-TNF therapy on CD31 and VEGF expression in colonic mucosa of Crohn's disease patients in relation to mucosal healing.

Eder P, Lykowska-Szuber L, Iwanik K, Krela-Kazmierczak I, Stawczyk-Eder K, Majewski P, Linke K, Kay EW, Wozniak A.

Folia Histochem Cytobiol. 2016;54(2):75-80. doi: 10.5603/FHC.a2016.0008. Epub 2016 Jun 8.

35.

Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer.

Dunne PD, McArt DG, Bradley CA, O'Reilly PG, Barrett HL, Cummins R, O'Grady T, Arthur K, Loughrey MB, Allen WL, McDade SS, Waugh DJ, Hamilton PW, Longley DB, Kay EW, Johnston PG, Lawler M, Salto-Tellez M, Van Schaeybroeck S.

Clin Cancer Res. 2016 Aug 15;22(16):4095-104. doi: 10.1158/1078-0432.CCR-16-0032. Epub 2016 May 5.

36.

Targeting the 19S proteasomal subunit, Rpt4, for the treatment of colon cancer.

Boland K, Flanagan L, McCawley N, Pabari R, Kay EW, McNamara DA, Murray F, Byrne AT, Ramtoola Z, Concannon CG, Prehn JH.

Eur J Pharmacol. 2016 Jun 5;780:53-64. doi: 10.1016/j.ejphar.2016.03.031. Epub 2016 Mar 17.

PMID:
26997367
37.

Low levels of Caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer: Caspase-3 inhibition as a therapeutic approach.

Flanagan L, Meyer M, Fay J, Curry S, Bacon O, Duessmann H, John K, Boland KC, McNamara DA, Kay EW, Bantel H, Schulze-Bergkamen H, Prehn JH.

Cell Death Dis. 2016 Feb 4;7:e2087. doi: 10.1038/cddis.2016.7.

38.

LC3B globular structures correlate with survival in esophageal adenocarcinoma.

El-Mashed S, O'Donovan TR, Kay EW, Abdallah AR, Cathcart MC, O'Sullivan J, O'Grady A, Reynolds J, O'Reilly S, O'Sullivan GC, McKenna SL.

BMC Cancer. 2015 Aug 12;15:582. doi: 10.1186/s12885-015-1574-5. Erratum in: BMC Cancer. 2019 Dec 3;19(1):1177.

39.

Relationship between serum response factor and androgen receptor in prostate cancer.

Prencipe M, O'Neill A, O'Hurley G, Nguyen LK, Fabre A, Bjartell A, Gallagher WM, Morrissey C, Kay EW, Watson RW.

Prostate. 2015 Nov;75(15):1704-17. doi: 10.1002/pros.23051. Epub 2015 Aug 7.

40.

High levels of X-linked Inhibitor-of-Apoptosis Protein (XIAP) are indicative of radio chemotherapy resistance in rectal cancer.

Flanagan L, Kehoe J, Fay J, Bacon O, Lindner AU, Kay EW, Deasy J, McNamara DA, Prehn JH.

Radiat Oncol. 2015 Jun 13;10:131. doi: 10.1186/s13014-015-0437-1.

41.

Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.

Jennings CJ, Murer B, O'Grady A, Hearn LM, Harvey BJ, Kay EW, Thomas W.

Br J Cancer. 2015 Jun 30;113(1):69-75. doi: 10.1038/bjc.2015.187. Epub 2015 Jun 9.

42.

CD44 increases the efficiency of distant metastasis of breast cancer.

McFarlane S, Coulter JA, Tibbits P, O'Grady A, McFarlane C, Montgomery N, Hill A, McCarthy HO, Young LS, Kay EW, Isacke CM, Waugh DJ.

Oncotarget. 2015 May 10;6(13):11465-76.

43.

Diagnostic potential of zinc finger protein-specific autoantibodies and associated linear B-cell epitopes in colorectal cancer.

O'Reilly JA, Fitzgerald J, Fitzgerald S, Kenny D, Kay EW, O'Kennedy R, Kijanka GS.

PLoS One. 2015 Apr 13;10(4):e0123469. doi: 10.1371/journal.pone.0123469. eCollection 2015.

44.

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.

van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, Power DG, Regan PJ, McDermott CM, O'Keeffe A, Orosz Z, Donnellan PP, Crown JP, Hennessy BT, Gallagher WM.

Melanoma Res. 2015 Jun;25(3):189-99. doi: 10.1097/CMR.0000000000000149.

PMID:
25746038
45.

High CerS5 expression levels associate with reduced patient survival and transition from apoptotic to autophagy signalling pathways in colorectal cancer.

Fitzgerald S, Sheehan KM, Espina V, O'Grady A, Cummins R, Kenny D, Liotta L, O'Kennedy R, Kay EW, Kijanka GS.

J Pathol Clin Res. 2014 Nov 17;1(1):54-65. doi: 10.1002/cjp2.5. eCollection 2015 Jan.

46.

Protective role for caspase-11 during acute experimental murine colitis.

Oficjalska K, Raverdeau M, Aviello G, Wade SC, Hickey A, Sheehan KM, Corr SC, Kay EW, O'Neill LA, Mills KH, Creagh EM.

J Immunol. 2015 Feb 1;194(3):1252-60. doi: 10.4049/jimmunol.1400501. Epub 2014 Dec 29.

47.

BCL2 protein signalling determines acute responses to neoadjuvant chemoradiotherapy in rectal cancer.

Flanagan L, Lindner AU, de Chaumont C, Kehoe J, Fay J, Bacon O, Toomey S, Huber HJ, Hennessy BT, Kay EW, McNamara DA, Prehn JH.

J Mol Med (Berl). 2015 Mar;93(3):315-26. doi: 10.1007/s00109-014-1221-7. Epub 2014 Nov 13.

PMID:
25388617
48.

Global DNA methylation is altered by neoadjuvant chemoradiotherapy in rectal cancer and may predict response to treatment - A pilot study.

Tsang JS, Vencken S, Sharaf O, Leen E, Kay EW, McNamara DA, Deasy J, Mulligan ED.

Eur J Surg Oncol. 2014 Nov;40(11):1459-66. doi: 10.1016/j.ejso.2014.06.008. Epub 2014 Jul 28.

PMID:
25108814
49.

The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study.

Abdul-Jalil KI, Sheehan KM, Toomey S, Schmid J, Prehn J, O'Grady A, Cummins R, O'Neill B, McNamara DA, Deasy J, Breathnach O, Grogan L, Rogers A, Doherty G, Winter D, Ryan J, El-Masry S, Gibbons D, Sheahan K, Gillen P, Kay EW, Hennessy BT.

Ann Surg Oncol. 2014 Aug;21(8):2642-9. doi: 10.1245/s10434-014-3658-x. Epub 2014 Apr 4.

PMID:
24700299
50.

Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer.

Cathcart MC, Gately K, Cummins R, Drakeford C, Kay EW, O'Byrne KJ, Pidgeon GP.

Biochim Biophys Acta. 2014 May;1842(5):747-55. doi: 10.1016/j.bbadis.2014.01.011. Epub 2014 Jan 28.

Supplemental Content

Support Center